Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics

Abstract

The simultaneous detection of multiple somatic mutations in the context of molecular diagnostics of cancer is frequently performed by means of amplicon-based targeted next-generation sequencing (NGS). However, only few studies are available comparing multicenter testing of different NGS platforms and gene panels. Therefore, seven partner sites of the German Cancer Consortium (DKTK) performed a multicenter interlaboratory trial for targeted NGS using the same formalin-fixed, paraffin-embedded (FFPE) specimen of molecularly pre-characterized tumors (n = 15; each n = 5 cases of Breast, Lung, and Colon carcinoma) and a colorectal cancer cell line DNA dilution series. Detailed information regarding pre-characterized mutations was not disclosed to the partners. Commercially available and custom-designed cancer gene panels were used for library preparation and subsequent sequencing on several devices of two NGS different platforms. For every case, centrally extracted DNA and FFPE tissue sections for local processing were delivered to each partner site to be sequenced with the commercial gene panel and local bioinformatics. For cancer-specific panel-based sequencing, only centrally extracted DNA was analyzed at seven sequencing sites. Subsequently, local data were compiled and bioinformatics was performed centrally. We were able to demonstrate that all pre-characterized mutations were re-identified correctly, irrespective of NGS platform or gene panel used. However, locally processed FFPE tissue sections disclosed that the DNA extraction method can affect the detection of mutations with a trend in favor of magnetic bead-based DNA extraction methods. In conclusion, targeted NGS is a very robust method for simultaneous detection of various mutations in FFPE tissue specimens if certain pre-analytical conditions are carefully considered.

Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience

“…and produced by Illumina, San Diego, CA), a BRCA1/2 panel (produced by Illumina), a hotspot 48-gene panel (TruSeq Amplicon Cancer Panel, Illumina), and a 54-gene myeloid panel (TruSight Myeloid Sequencing Panel, Illumina). 15 - 17 …”

Third-Generation Sequencing in the Clinical Laboratory: Exploring the Advantages and Challenges of Nanopore Sequencing

“…NGS in the clinical setting has become widespread in personalized medicine due to its ability to characterize variants throughout the human genome. The Illumina and Thermo Fisher platforms are in widespread use to identify somatic mutations in cancer and to uncover the genetic basis of various inherited diseases (5,6). Application of NGS to infectious disease diagnostics has been slower to evolve for a number of reasons.…”

Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients

“…The guidelines allowing optimization of the procedures of the different analyzes using LB have to be better standardized. Multi-centric and independent validation studies need to be systematically set up to evaluate the reproducibility and the robustness of the different techniques as well as to better control the different steps of the pre-analytical phases [ 122 , 123 , 124 ]. So, a number of initiatives aimed at establishing new recommendations and guidelines have started to emerge [ 125 , 126 , 127 ].…”